von Willebrand Factor/VWF Antibody (F8/86): sc-53466

VWF Antibody (F8/86) is a mouse monoclonal IgG1 kappa light chain antibody designed to detect von Willebrand factor (VWF) protein with exceptional precision across various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). VWF is a complex multimeric glycoprotein composed of multiple repeating units, each containing distinct domains such as D′D3, A1, A2, A3, and C-terminal regions, which are critical for its role in hemostasis. This intricate structure allows VWF to effectively mediate platelet adhesion and aggregation at sites of vascular injury by interacting with glycoprotein Ib (GPIb) receptors on platelets and binding to collagen in the subendothelial matrix. Additionally, the multimeric nature of VWF enhances its ability to serve as a carrier for Factor VIII, a vital cofactor in the coagulation cascade, thereby ensuring the stability and availability of Factor VIII during clot formation. The structural integrity of VWF, maintained through posttranslational modifications such as propeptide cleavage and the formation of intersubunit disulfide bonds, is essential for functionality and ability to prevent excessive bleeding, as defects in VWF structure are the underlying cause of von Willebrand disease, the most common inherited bleeding disorder. Anti-VWF antibody (F8/86) is raised against VWF isolated from human plasma, and is available in both non-conjugated and various conjugated forms including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® variants to accommodate diverse experimental needs. By enabling accurate detection and analysis of VWF′s structural domains and multimeric forms, VWF monoclonal antibody (F8/86) facilitates in-depth studies into the molecular mechanisms of blood coagulation, the regulation of hemostatic balance, and the pathophysiology of bleeding disorders. Whether utilized in basic research to explore the structural dynamics of VWF or in clinical diagnostics to assess VWF levels and functionality in patient samples, VWF (F8/86) antibody serves as a useful tool for studying vascular biology and the development of therapeutic strategies for managing coagulation-related conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

von Willebrand Factor/VWF Antibody (F8/86) References:

1. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.  |  Wise, RJ., et al. 1991. J Biol Chem. 266: 21948-55. PMID: 1939217
2. The value of immunohistological screening in the production of monoclonal antibodies.  |  Naiem, M., et al. 1982. J Immunol Methods. 50: 145-60. PMID: 6806388
3. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.  |  Fischer, BE., et al. 1996. Thromb Res. 84: 55-66. PMID: 8885147
4. Binding of the von Willebrand factor A1 domain to histone.  |  Ward, CM., et al. 1997. Thromb Res. 86: 469-77. PMID: 9219327
5. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.  |  Jenkins, PV., et al. 1998. Blood. 91: 2032-44. PMID: 9490688
6. Molecular genetics of von Willebrand disease.  |  Mazurier, C., et al. 1998. Ann Genet. 41: 34-43. PMID: 9599650
7. Binding of factor VIII to von willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers.  |  Bendetowicz, AV., et al. 1998. Blood. 92: 529-38. PMID: 9657753

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-von Willebrand Factor/VWF Antibody (F8/86) has 31 citations in a variety of scientific publications.

Primary antibodies like Anti-von Willebrand Factor/VWF Antibody (F8/86) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

von Willebrand Factor/VWF Antibody (F8/86) Specifications

Alternate Product Name: von Willebrand factor

Product Clone Name: F8/86

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: VWF

Epitope Species: human

Product Reactivity/Detection: VWF

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 31 citations in various scientific publications

Available Conjugates/Forms for von Willebrand Factor/VWF Antibody (F8/86): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin